Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.

<h4>Background</h4>Antiplatelet agents are commonly used for cardiovascular diseases, but their pleiotropic effects in critically ill patients are controversial. We therefore performed a meta-analysis of cohort studies to investigate the effect of antiplatelet therapy in the critically i...

Full description

Saved in:
Bibliographic Details
Main Authors: Lijun Wang, Heng Li, Xiaofei Gu, Zhen Wang, Su Liu, Liyong Chen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0154754&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849723462183026688
author Lijun Wang
Heng Li
Xiaofei Gu
Zhen Wang
Su Liu
Liyong Chen
author_facet Lijun Wang
Heng Li
Xiaofei Gu
Zhen Wang
Su Liu
Liyong Chen
author_sort Lijun Wang
collection DOAJ
description <h4>Background</h4>Antiplatelet agents are commonly used for cardiovascular diseases, but their pleiotropic effects in critically ill patients are controversial. We therefore performed a meta-analysis of cohort studies to investigate the effect of antiplatelet therapy in the critically ill.<h4>Methods</h4>Nine cohort studies, retrieved from PubMed and Embase before November 2015, involving 14,612 critically ill patients and 4765 cases of antiplatelet users, were meta-analysed. The main outcome was hospital or 30-day mortality. Secondary outcome was acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). Random- or fixed-effect models were taken for quantitative synthesis of the data.<h4>Results</h4>Antiplatelet therapy was associated with decreased mortality (odds ratio (OR) 0.61; 95% confidence interval (CI), 0.52-0.71; I2 = 0%; P <0. 001) and ARDS/ALI (OR 0.64; 95% CI, 0.50-0.82; I2 = 0%; P <0. 001). In every stratum of subgroups, similar findings on mortality reduction were consistently observed in critically ill patients.<h4>Conclusions</h4>Antiplatelet therapy is associated with reduced mortality and lower incidence of ARDS/ALI in critically ill patients, particularly those with predisposing conditions such as high-risk surgery, trauma, pneumonia, and sepsis. However, it remains unclear whether similar findings can be observed in the unselected and broad population with critical illness.
format Article
id doaj-art-35f41c80f8f84dee9acf8197f329038c
institution DOAJ
issn 1932-6203
language English
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-35f41c80f8f84dee9acf8197f329038c2025-08-20T03:11:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015475410.1371/journal.pone.0154754Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.Lijun WangHeng LiXiaofei GuZhen WangSu LiuLiyong Chen<h4>Background</h4>Antiplatelet agents are commonly used for cardiovascular diseases, but their pleiotropic effects in critically ill patients are controversial. We therefore performed a meta-analysis of cohort studies to investigate the effect of antiplatelet therapy in the critically ill.<h4>Methods</h4>Nine cohort studies, retrieved from PubMed and Embase before November 2015, involving 14,612 critically ill patients and 4765 cases of antiplatelet users, were meta-analysed. The main outcome was hospital or 30-day mortality. Secondary outcome was acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). Random- or fixed-effect models were taken for quantitative synthesis of the data.<h4>Results</h4>Antiplatelet therapy was associated with decreased mortality (odds ratio (OR) 0.61; 95% confidence interval (CI), 0.52-0.71; I2 = 0%; P <0. 001) and ARDS/ALI (OR 0.64; 95% CI, 0.50-0.82; I2 = 0%; P <0. 001). In every stratum of subgroups, similar findings on mortality reduction were consistently observed in critically ill patients.<h4>Conclusions</h4>Antiplatelet therapy is associated with reduced mortality and lower incidence of ARDS/ALI in critically ill patients, particularly those with predisposing conditions such as high-risk surgery, trauma, pneumonia, and sepsis. However, it remains unclear whether similar findings can be observed in the unselected and broad population with critical illness.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0154754&type=printable
spellingShingle Lijun Wang
Heng Li
Xiaofei Gu
Zhen Wang
Su Liu
Liyong Chen
Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.
PLoS ONE
title Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.
title_full Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.
title_fullStr Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.
title_full_unstemmed Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.
title_short Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.
title_sort effect of antiplatelet therapy on acute respiratory distress syndrome and mortality in critically ill patients a meta analysis
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0154754&type=printable
work_keys_str_mv AT lijunwang effectofantiplatelettherapyonacuterespiratorydistresssyndromeandmortalityincriticallyillpatientsametaanalysis
AT hengli effectofantiplatelettherapyonacuterespiratorydistresssyndromeandmortalityincriticallyillpatientsametaanalysis
AT xiaofeigu effectofantiplatelettherapyonacuterespiratorydistresssyndromeandmortalityincriticallyillpatientsametaanalysis
AT zhenwang effectofantiplatelettherapyonacuterespiratorydistresssyndromeandmortalityincriticallyillpatientsametaanalysis
AT suliu effectofantiplatelettherapyonacuterespiratorydistresssyndromeandmortalityincriticallyillpatientsametaanalysis
AT liyongchen effectofantiplatelettherapyonacuterespiratorydistresssyndromeandmortalityincriticallyillpatientsametaanalysis